STADA Arzneimittel AG (ETR:SAZ) received a €82.00 ($95.35) target price from stock analysts at Independent Research GmbH in a research note issued to investors on Friday. The brokerage currently has a “neutral” rating on the stock. Independent Research GmbH’s price objective indicates a potential upside of 0.87% from the stock’s previous close.
Several other equities analysts have also recently weighed in on SAZ. S&P Global set a €66.25 ($77.03) price target on STADA Arzneimittel AG and gave the company a “neutral” rating in a report on Thursday, August 3rd. Commerzbank Ag set a €58.00 ($67.44) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Wednesday, August 16th. Warburg Research set a €66.25 ($77.03) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Friday, August 18th. Finally, Nord/LB set a €65.53 ($76.20) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Thursday, August 31st. Four investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. STADA Arzneimittel AG currently has an average rating of “Sell” and a consensus price target of €71.43 ($83.06).
STADA Arzneimittel AG (ETR SAZ) opened at €81.29 ($94.52) on Friday. STADA Arzneimittel AG has a 12-month low of €41.41 ($48.15) and a 12-month high of €84.20 ($97.91).
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/12/stada-arzneimittel-ag-saz-pt-set-at-82-00-by-independent-research-gmbh.html.
About STADA Arzneimittel AG
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.